Federal award (DEFINITIVE CONTRACT, fiscal year 2024)
Recipient: REVAGENIX INC
Awarding agency: Department of Health and Human Services / National Institutes of Health
Funding agency: Department of Health and Human Services / National Institutes of Health
Period of performance: 2020-07-01 to 2025-08-31
Current total value of award: $24810588.61
Description: TO SELECT A NOVEL SMALL MOLECULE ANTIBIOTIC FOR CLINICAL DEVELOPMENT AND ADVANCE IT THROUGH IND FILING AND PHASE 1 CLINICAL STUDIES.